Abstract It is generally accepted that the presence of a competitive antagonist shifts an agonist concentration-response curve to the right. However, this may not always be the case: The concentration-response curve of an inverse receptor agonist may be shifted to the left by a neutral antagonist; a condition, which can be hypothetically explained by the assumption of both negative cooperativity of dimeric receptors plus a receptor reserve.
The presence of a competitive antagonist usually shifts an agonist concentration-response curve to the right. As it can be learned from the paper of Jergas et al. (2014) , O-2050, assumingly a neutral CB 1 receptor antagonist, indeed shifts the concentration-response curve of the classical CB 1 receptor agonist WIN 55,212-2 to the right. The concentrationresponse curve of the inverse CB 1 receptor agonist rimonabant, however, is shifted to the left by O-2050. What is the explanation for this puzzling finding?
By definition, a neutral competitive antagonist only changes the affinity of an agonist. Nevertheless, under the following assumptions, such a sole decrease in the agonist affinity can explain an increase in the potency of an inverse agonist, as observed by Jergas et al. (2014) , i.e., a shift to the left of its concentration-response curve. 3. Inverse agonist activation of only one subunit of the dimer is already sufficient to maximally reduce the constitutive 35 S-GTPγS binding of a CB 1 receptor dimer (receptor reserve). 4. Cooperativity has to be assumed for inverse agonist activation of the dimer. This is suggested by the position on the right of the rimonabant concentration-response curve compared to its concentration-binding curve.
In the study of Jergas et al. (2014) , the pK d of rimonabant, 7.8, was much higher than its pEC 50 , 5.0. To take this into consideration, the condition of cooperativity has to be assumed in addition to that of a receptor reserve (for quantification of the differences between pK d and pEC 50 see Limberger 1999 and Sauermann 2005) . Cooperativity means that two inverse agonists bind "non-independently" of each other to the CB 1 receptor dimer. We don't know explicitly from the data of Jergas et al. (2014) whether this cooperativity is positive or negative or neutral with respect to the binding affinities at the first and the second receptor of the dimer, although negative cooperativity may occur more often (Franco et al. 2007 ). We may only say that two inverse agonist molecules bind simultaneously to one CB 1 receptor dimer, and that binding of only one inverse agonist molecule is also sufficient to maximally reduce the constitutive 35 S-GTPγS binding. Cooperativity results in a position of such a four-molecular (two inverse agonists plus two CB 1 receptors) concentration-response curve far on the right, as compared with a binding curve which reflects a bimolecular association of an inverse agonist to a single CB 1 receptor. The mentioned receptor reserve per se shifts the inverse agonist concentration-response curve to the left; this left shift, however, is largely overcompensated by the cooperativity-induced right shift.
How can we now explain that the presence of the pure neutral antagonist O-2050 enhanced the inhibitory action of rimonabant (i.e., shifted its concentration-response curve to the left)? The pK d of O-2050, 6.8, was assessed convincingly (note that this pK d of 6.8 was very similar to the pA 2 of 7.0, Jergas et al. 2014) .
First, some binomial considerations have to be made: these considerations may mathematically develop concentrationresponse functions from concentration-binding functions (e.g. Feuerstein and Limberger 1999) .
The functional system, usually consisting of multiple functional units (cells or nerve terminals endowed with receptors), is currently represented by constitutively active CB 1 receptor dimers, each with receptors 1 and 2. As already said, inverse activation of both dimeric receptors does not result in a larger 35 S-GTPγS binding reduction than activation of only one. The total number of receptors per dimer is n=2; the number of occupied receptors is i=0, 1, or 2; the assumption of a receptor reserve defines i=1 for the (minimal) number of dimeric receptors which have to be activated to obtain a maximum agonist effect.
If 0<i≤n, or 0<1, 2≤2, the number i of occupied receptors has a binomial distribution B(n, q) with parameters n=2 and q. For i=0, no receptor of the dimer is occupied, for i=1 or 2, one or two receptors are occupied, n=2 is the maximum number of receptors occupied. q is the fractional receptor occupation, 
Occupancy by 1μM O-2050 alone
The pK d of the pure antagonist O-2050 is 6.8. Then, at 1 μM, the fractional receptor occupation q= The probabilities that, at the different rimonabant concentrations, no receptor, one of two receptors, or both receptors are occupied are given in Table 1 below.
The probability that one of two receptors is occupied, for instance, at 10μM rimonabant, is 0.0032. Thus, 0.32 % of all dimers have only one of two receptor activated by rimonabant. These 0.32 % shows already maximally reduced constitutive activity to bind 35 S-GTPγS. The probability that, at 10μM rimonabant, both receptors of a dimer are occupied, is 0.9968. Thus, 99.68 % of all dimers have two receptors activated by rimonabant which means that the 35 S-GTPγS binding of these 99.68 % is inhibited, but only to the same degree as if one of both receptors were occupied by rimonabant. Table 1 shows the probabilities for occupations by rimonabant of one of two dimeric receptors in the absence and presence of 1 μM O-2050. These probabilities P correspond to the frequencies of occurrence of dimers with one of two receptors occupied by rimonabant.
With the assumption of negative cooperativity as intramolecular cross-talk in the CB 1 receptor dimer, we can now explain that the concentration-response curve of the inverse CB 1 receptor agonist rimonabant is shifted to the left by O-2050. The binding of one rimonabant molecule to one receptor negatively affects the binding of the second rimonabant molecule to the partner receptor. This implies the lack of involvement of intracellular signaling and suggests some kind of cooperative interaction between adjacent receptors (Franco et al. 2007 ). Table 1 clearly shows that the frequency of the condition "only one of the two dimer receptors is occupied" is always higher in the presence of O-2050. This means that negative cooperativity, i.e., a decrease in the binding affinity for rimonabant, occurs more rarely in the presence of the neutral antagonist. Since, according to the assumed receptor reserve, the inverse activation of only one receptor of the dimer is sufficient to maximally inhibit the constitutive activity of this dimer, the inverse agonist effect occurs at lower agonist concentrations, due to the relatively increased (i.e., not decreased) inverse agonist affinity to only one of the two dimer receptors. This results in an increased inhibitory effect of rimonabant, i.e., a shift to the left of its concentration-response curve in the presence of a neutral antagonist.
We do not need to assume other than pure neutral antagonist actions of O-2050 to explain this shift to the left. Admittedly, other assumptions had to be made, i.e., a receptor reserve in the rimonabant action and negative cooperativity in the rimonabant binding to the dimer receptors. These other assumptions seem possible or even probable. However, they are not yet experimentally verified, at least not in the paper of Jergas et al. (2014) under consideration.
Whether the approach of this editorial, to make two additional assumptions (receptor reserve and negative cooperativity) and to deny the assumption of Jergas et al. (2014 Jergas et al. ( , O-2050 In summary, the pure neutral antagonist O-2050 increases the inverse agonistic activity of rimonabant. Under the assumptions made, there is no need to attribute other qualities to O-2050 than pure neutral antagonist properties. 
